Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
floretyrosine (18F)
- Development stage
- Approved
- Lead developer
- Curium
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
floretyrosine (18F) (also known as 18F-FET or O-(2-[18F]fluoroethyl)-L-tyrosine) is a radioactive diagnostic radiopharmaceutical used with positron emission tomography (PET) imaging. It is a synthetic amino acid analogue labeled with the positron-emitting radioisotope fluorine-18. Floretyrosine (18F) is actively transported into cells via L-type amino acid transporters (specifically LAT1 and LAT2), which are significantly upregulated in tumor cells, particularly gliomas, compared to healthy brain tissue. Unlike 18F-FDG, floretyrosine (18F) has low uptake in normal brain tissue and inflammatory cells, providing a high tumor-to-background ratio. It is primarily indicated to differentiate recurrent or progressive glioma from treatment-related changes (such as pseudoprogression or radiation necrosis) in adult and pediatric patients. It is also being evaluated for the diagnosis of brain metastases.
- Brand names
- IASOglioPixclara
- Other names
- 18F-FET2-fluoroethyltyrosine F-18FET F-18floretyrosine (18F)floretyrosine F 18floretyrosine F-18floretyrosine F18fluoroethyl-L-tyrosine (18F)fluoroethyltyrosine F-18L-tyrosine, O-[2-(fluoro-18F)ethyl]-O-(2-[18F]fluoroethyl)-L-tyrosineO-(2-[¹⁸F]fluoroethyl)-L-tyrosineO-[2-(fluoro-18F)ethyl]-L-tyrosine
02
Targets
SLC7A5 (Large neutral amino acid transporter small subunit 1)LAT2 (Linker for activation of T cells family member 2)
Beyond the preview
Go deeper on floretyrosine (18F).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on floretyrosine (18F).